Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study

Authors: Andrew Dean, Sanjeev Gill, Mark McGregor, Vy Broadbridge, Harri A Järveläinen, Timothy Price

Published: 2022-07-06

DOI: 10.1016/s2468-1253(22)00167-4

Source: Full article

---

Abstract

No abstract found.